vs
KKR Real Estate Finance Trust Inc.（KREF）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
KKR Real Estate Finance Trust Inc.的季度营收约是STANDARD BIOTOOLS INC.的1.3倍（$25.8M vs $19.6M），KKR Real Estate Finance Trust Inc.净利率更高（-101.7% vs -177.4%，领先75.7%），STANDARD BIOTOOLS INC.同比增速更快（-11.5% vs -26.6%），过去两年STANDARD BIOTOOLS INC.的营收复合增速更高（-12.2% vs -18.8%）
KKR房地产金融信托公司是全球投资机构KKR旗下的专业房地产金融平台，主要发起、收购并管理优先担保商业地产贷款组合，抵押物多为美国各地的优质机构级商业地产，通过贷款利息收入为投资者提供稳定的经风险调整后的回报。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
KREF vs LAB — 直观对比
营收规模更大
KREF
是对方的1.3倍
$19.6M
营收增速更快
LAB
高出15.1%
-26.6%
净利率更高
KREF
高出75.7%
-177.4%
两年增速更快
LAB
近两年复合增速
-18.8%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $25.8M | $19.6M |
| 净利润 | $-26.2M | $-34.7M |
| 毛利率 | — | 48.5% |
| 营业利润率 | -105.1% | -168.5% |
| 净利率 | -101.7% | -177.4% |
| 营收同比 | -26.6% | -11.5% |
| 净利润同比 | -229.6% | -28.8% |
| 每股收益（稀释后） | $-0.49 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收KREFLAB
| Q4 25 | $25.8M | — | ||
| Q3 25 | $25.3M | $19.6M | ||
| Q2 25 | $30.2M | $21.8M | ||
| Q1 25 | $31.3M | $40.8M | ||
| Q4 24 | $35.1M | — | ||
| Q3 24 | $37.0M | $22.1M | ||
| Q2 24 | $40.4M | $22.5M | ||
| Q1 24 | $39.1M | $45.5M |
净利润KREFLAB
| Q4 25 | $-26.2M | — | ||
| Q3 25 | $13.8M | $-34.7M | ||
| Q2 25 | $-29.7M | $-33.5M | ||
| Q1 25 | $-4.9M | $-26.0M | ||
| Q4 24 | $20.3M | — | ||
| Q3 24 | $-7.4M | $-26.9M | ||
| Q2 24 | $25.8M | $-45.7M | ||
| Q1 24 | $-3.1M | $-32.2M |
毛利率KREFLAB
| Q4 25 | — | — | ||
| Q3 25 | — | 48.5% | ||
| Q2 25 | — | 48.8% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 54.9% | ||
| Q2 24 | — | 46.1% | ||
| Q1 24 | — | 53.1% |
营业利润率KREFLAB
| Q4 25 | -105.1% | — | ||
| Q3 25 | 50.4% | -168.5% | ||
| Q2 25 | -101.3% | -118.1% | ||
| Q1 25 | -18.3% | -80.8% | ||
| Q4 24 | 55.8% | — | ||
| Q3 24 | -19.6% | -120.9% | ||
| Q2 24 | 63.3% | -134.5% | ||
| Q1 24 | -8.7% | -132.2% |
净利率KREFLAB
| Q4 25 | -101.7% | — | ||
| Q3 25 | 54.4% | -177.4% | ||
| Q2 25 | -98.5% | -153.7% | ||
| Q1 25 | -15.5% | -63.8% | ||
| Q4 24 | 57.7% | — | ||
| Q3 24 | -20.0% | -122.0% | ||
| Q2 24 | 63.9% | -203.3% | ||
| Q1 24 | -7.9% | -70.6% |
每股收益（稀释后）KREFLAB
| Q4 25 | $-0.49 | — | ||
| Q3 25 | $0.12 | $-0.09 | ||
| Q2 25 | $-0.53 | $-0.09 | ||
| Q1 25 | $-0.15 | $-0.07 | ||
| Q4 24 | $0.22 | — | ||
| Q3 24 | $-0.19 | $-0.07 | ||
| Q2 24 | $0.29 | $-0.12 | ||
| Q1 24 | $-0.13 | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $84.6M | $129.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.2B | $399.7M |
| 总资产 | $6.5B | $539.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资KREFLAB
| Q4 25 | $84.6M | — | ||
| Q3 25 | $204.1M | $129.4M | ||
| Q2 25 | $107.7M | $158.6M | ||
| Q1 25 | $106.4M | $150.9M | ||
| Q4 24 | $104.9M | — | ||
| Q3 24 | $108.8M | $210.6M | ||
| Q2 24 | $107.2M | $269.8M | ||
| Q1 24 | $106.5M | $287.1M |
总债务KREFLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M |
股东权益KREFLAB
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | $399.7M | ||
| Q2 25 | $1.2B | $424.5M | ||
| Q1 25 | $1.3B | $454.6M | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.4B | $489.3M | ||
| Q2 24 | $1.4B | $510.3M | ||
| Q1 24 | $1.4B | $577.3M |
总资产KREFLAB
| Q4 25 | $6.5B | — | ||
| Q3 25 | $6.5B | $539.6M | ||
| Q2 25 | $6.8B | $557.0M | ||
| Q1 25 | $6.6B | $579.6M | ||
| Q4 24 | $6.4B | — | ||
| Q3 24 | $6.8B | $681.5M | ||
| Q2 24 | $7.1B | $708.7M | ||
| Q1 24 | $7.3B | $777.7M |
负债/权益比KREFLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $72.3M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-23.1M |
| 自由现金流率自由现金流/营收 | — | -118.1% |
| 资本支出强度资本支出/营收 | — | 4.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-111.1M |
8季度趋势，按日历期对齐
经营现金流KREFLAB
| Q4 25 | $72.3M | — | ||
| Q3 25 | $18.5M | $-22.2M | ||
| Q2 25 | $21.1M | $-20.7M | ||
| Q1 25 | $15.9M | $-30.3M | ||
| Q4 24 | $132.6M | — | ||
| Q3 24 | $49.1M | $-27.9M | ||
| Q2 24 | $30.6M | $-39.0M | ||
| Q1 24 | $34.5M | $-62.5M |
自由现金流KREFLAB
| Q4 25 | — | — | ||
| Q3 25 | — | $-23.1M | ||
| Q2 25 | — | $-22.6M | ||
| Q1 25 | — | $-35.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-30.1M | ||
| Q2 24 | — | $-41.0M | ||
| Q1 24 | — | $-63.3M |
自由现金流率KREFLAB
| Q4 25 | — | — | ||
| Q3 25 | — | -118.1% | ||
| Q2 25 | — | -103.6% | ||
| Q1 25 | — | -86.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -136.4% | ||
| Q2 24 | — | -182.2% | ||
| Q1 24 | — | -138.9% |
资本支出强度KREFLAB
| Q4 25 | — | — | ||
| Q3 25 | — | 4.5% | ||
| Q2 25 | — | 8.7% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 10.2% | ||
| Q2 24 | — | 8.6% | ||
| Q1 24 | — | 1.7% |
现金转化率KREFLAB
| Q4 25 | — | — | ||
| Q3 25 | 1.34× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 6.54× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.19× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KREF
暂无分部数据
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
